Effect of parenteral vitamin D
(D3) on albuminuria in T2DM patients
Wani Z1,
Telwani A2, Wani
S 3, Shah A.4, Ummer J5
1Dr. Zahid Wani, 2Dr. Ajaz Telwani ,
Senior Resident Department of
Medicine, SKIMS Medical College Hospitals, Srinagar, Jammu
Kashmir, India, 3Dr. Shahid Wani, Senior
Resident Department
of Paediatrics, Government Medical College Srinagar, Jammu Kashmir,
India, 4Dr. Aejaz Shah, Senior Resident
Department of
Medicine, SKIMS Medical College Hospitals, Srinagar, Jammu
Kashmir, India, 5Dr. Ummer Jalalie, Senior
Resident
Department of Medicine, SKIMS Medical College & Hospitals,
Srinagar, Jammu Kashmir, India.
Address for
Correspondence: Dr Ajaz Ahmad Telwani. Email:
ajaz917@yahoo.com
Abstract
Background:
Vitamin D deficiency is a common disorder in diabetic patients and may
be a risk factor for progression of diabetic nephropathy. The aim of
our study was to assess the effects of large dose of parentral Vitamin
D on 24 hours albuminuria in T2DM patients. This is a first study of
its kind, where we used single large dose parental vitamin D. Methods: This
prospective single center study included 50 vitamin D deficient [25(OH)
D <50 nmol/l] T2DM patients with an adequate glycemic control
(HbA1c< 7.0%). Without any changes in anti-hyperglycemic or
antihypertensive drugs, these patients were given a single high dose
(600000 IU) of parenteral Vitamin D3. Then the changes in Vitamin D
levels and 24 hours albuminuria were seen on follow up at 3 months. Results: Vitamin D3
supplementation improved 24 hrs albuminuria. In this study twenty-four
hour urinary albumin excretion decreased from 200.4 ± 103.3
to 198.4 ± 105.0 mg/24 hrs (p value 0.015). In males it
changed from 212.1 ± 95.4 to 209.6 ± 96.9 (p
value 0.046) and in females it changed from 188.6 ± 111.3 to
186.8 ± 112.9. (P value 0.041) .There was a negative
association of albuminuria with Vit D levels in our study with p value
=0.001 at 3 months of follow up. Conclusion:
Vitamin D3 supplementation significantly reduces 24 hour urinary
albumin excretion in T2DM patients with Vitamin D3 deficiency.
Keywords:
Albuminuria, RAS -Renin-Angiotensin System, T2DM-Type 2 Diabetes
Mellitus, Vitamin D.
Manuscript received:
04th June 2017, Reviewed:
12th June 2017
Author Corrected:
20th June 2017, Accepted
for Publication: 30th June 2017
Introduction
Diabetic nephropathy is the leading cause of chronic renal disease and
a major cause of cardiovascular mortality. Diabetic nephropathy is
staged on the basis of albuminuria and it is a marker for kidney injury
[1]. In the pathogenesis of diabetic nephropathy multiple pathways are
engaged and the intrarenal RAS is activated [2]. Vitamin D3 negatively
regulates the renin–angiotensin system (RAS) as it suppresses
renin biosynthesis [3]. Therefore constant low vitamin D level can
worsen the renal injury in the diabetic patients. Vitamin D is vital
for maintaining podocyte health, preventing epithelial-to-mesenchymal
transformation and suppressing inflammation [4]. Replacement with
pharmacologic dosages of vitamin D receptor agonists have consistently
shown reduction in albuminuria [5] and glomerular inflammation and
decreases in the renal fibrosis progression [6]. Emerging evidence in
patients with nephropathy shows that vitamin D can reduce albuminuria
even in the presence of angiotensin-converting enzyme inhibition [7].
In addition to reducing proteinuria, Vitamin D reduce insulin
resistance [8], blood pressure, inflammation and preserve podocyte
loss, providing biologic plausibility to the notion that the optimum
Vitamin D levels are renoprotective [9,10].
Aims
& Objectives
To eval¬uate the effect of Vitamin D in reducing
albuminuria in the type 2 diabetic patients with Vit D deficiency
Methods
Study design: Prospective
cohort study over a period of one year
Study setting: Department
of Medicine SKIMS Medical College & Hospitals Srinagar over a
period of one year from Nov 2015 to Nov 2016.
Inclusion criteria: All
Type 2 diabetic patients who fulfil the following were included in
study.
1) Adequate Glycemic Control (Hba1c < 7).
2) Albuminuria (> 30 mg/ 24 hours).
3) Vitamin D Deficiency (< 50 nmol/l).
Exclusion criteria
1) Uncooperative patients or unwilling to give
informed written consent.
2) Vit D or Calcium supplements consumption in
previous 3 months.
Participants:
50 consecutive Type 2 Diabetes Mellitus patients who presented to our
department and fulfilled the inclusion criteria.
Variables:
Age, Gender, Fasting Blood Glucose, Postprandial Blood Glucose, HbA1c,
Albuminuria, Vitamin D and Calcium.
Data source: Department
of medicine, SKIMS Medical College & Hospitals Srinagar, Jammu
& Kashmir, India
Statistical method: Statistical
analyses were performed by using SPSS 20. The difference in mean levels
of vitamin D and albuminuria before and after treatment with parenteral
vitamin D were determined by paired samples T test. Results were
considered significant with a P-value of less than 0.05.
The study was approved by clinical research and ethics committee of
institute. 50 patients of T2DM with Vitamin D deficiency and adequate
glycemic control were taken into study. Patients fulfilling the
inclusion criteria were apprised of the type of study being carried out
and their written consent was obtained. Vitamin D {25(OH) D} and 24 hr
urinary albumin levels were obtained at the baseline. One single dose
600000 unit vitamin D3 was given intramuscularly and changes in 24 hrs
albuminuria were seen on follow up at 3 months.
Results
Study included a total of 50 vitamin D deficient [25(OH) D
<50 nmol/l] T2DM patients with an adequate glycemic control. 30
out of 50 participants (60%) were above 50 years of age. After
supplementation with single high dose (600000 IU) of parenteral Vitamin
D3, 25(OH) D levels increased from 33.34 ± 4.19 to 56.12
± 4.70nmol/l. In males it improved from 33.99 ±
4.10 to 56.58 ± 4.89nmol/l and in females from 32.70
± 3.94 to55.65 ± 4.55 nmol/l (p value
<0.001) (Tab 1).
Tab-1: Vitamin D levels
in all patients before and after supplementation
Variables
|
Mean ± SD
|
p-value
|
Remarks
|
Vit. D (basal)
|
Vit. D (3 months)
|
All cases
|
33.34 ± 4.19
|
56.12 ± 4.70
|
< 0.001
|
S
|
Male
|
33.99 ± 4.10
|
56.58 ± 4.89
|
< 0.001
|
S
|
Female
|
32.70 ± 3.94
|
55.65 ± 4.55
|
< 0.001
|
S
|
Table-2: 24 hrs
albuminuria levels in all patients before& after vitamin D
supplementation
Variables
|
Mean ± SD
|
p-value
|
Remarks
|
Alb. (basal)
|
Alb. (3 months)
|
All cases
|
200.3 ± 103.3
|
198.2 ± 1054.8
|
0.005
|
S
|
Male
|
212.1 ± 95.4
|
209.6 ± 96.9
|
0.046
|
S
|
Female
|
188.6 ± 111.3
|
186.8 ± 112.9
|
0.041
|
S
|
Twenty-four-hour urinary albumin excretion decreased from
200.4 ± 103.3 to198.4 ± 105.0 (p value 0.015). In
males it changed from 212.1 ± 95.4 to 209.6 ±
96.9 (p value 0.046) and in females it changed from 188.6 ±
111.3 to 186.8 ± 112.9(p value 0.041) (Tab 2).
Discussion
Diabetic nephropathy is the most common cause of chronic kidney disease
and end stage renal disease, about 30% to 35% of dialysis patients have
diabetes [11]. Diabetes is also the most common cause of renal
replacement therapy requirement, in the United States [12]. Nephropathy
is the serious complication of diabetes, defined by the development of
protein¬uria. Proteinuria is the main predictor of chronic
kidney disease progression and it is now recognized as the first
therapeutic target in the management of chronic kidney disease [13-17].
Drugs that block the renin-angiotensin-aldosterone system (ARBs) are
effective in reducing proteinuria and slowing down progression of the
disease. ARBs are the first step in renoprotective antiproteinuric
treatment. However their antiproteinuric effect is usually suboptimal
and residual proteinuria continues to be a target for treatment, with
additional renoprotective agents. Clinically, many drugs have been
tested to reduce residual proteinuria and others are being tested.
Growing evidence supports a potential role for vitamin D receptor (VDR)
activation in reducing proteinuria. Vitamin D deficiency is highly
prevalent in patients with chronic kidney disease even in the early
stages [18-23]. In several studies, vitamin D deficiency is related to
albuminuria, lower glomerular filtration rate and chronic kidney
disease progression [18, 20, 24-27], Vitamin D metabolites inhibit the
renin-angiotensin system and prevent the glomerulosclerosis. Vitamin D
also decreases the insulin resistance and de¬creases blood
pressure as well [28,29]. Recently some studies were carried out
regarding the effect of Vitamin D supplementation on reducing
protein¬uria in diabetic patients. However the results of these
studies are controversial. Therefore we aimed to eval¬uate
effect of Vitamin D in reducing proteinuria in the type 2 diabetic
patients with Vitamin D deficiency.
Out of 50 diabetic patients included in the study, 30 (60%) were above
50 years of age .This is in accordance to the epidemiological evidence
of hypovitaminosis D being more prevalent in elderly [30] because they
produce 75% less cutaneous vitamin D3 than young adults. After
supplementation with parenteral Vitamin D3 circulating levels of
25-hydroxy vitamin D were adequate in patients at follow up. So
cholecalciferol via intramuscular route has effective and immediate
response resulting in improved levels. There was a significant decrease
in urinary albumin excretion on the follow up after Vitamin D was
replenished.
Ahmadi [31] et al, in a clinical trial on diabetic patients with
diabetic nephropathy and Vitamin D deficiency, found that Vitamin D
prescription for three months had not any effect on decreasing of
proteinuria. Kim [32] et al in the study on 63 diabetic patients with
nephropathy and low Vitamin D levels found that repletion with
cholecalciferol could decrease albuminuria. They concluded that
di¬etary Vitamin D in patients with diabetic nephropathy may
have a beneficial effect in delaying the progression of disease. Ali
Momeni [33] et al randomly enrolled 60 diabetic patients with
proteinuria and Vitamin D deficiency or insufficiency in two equal
groups. They saw that there was no difference between Vitamin D level
in case and control group at the beginning of the study, however at the
end of the study Vitamin D levels were significantly higher in the case
group. There was no difference in proteinuria between case and control
group at the beginning and the end of the study, while a significant
difference between the changes of proteinuria before and after the
study were seen in two groups . Bonakdaran [34] et al, found a
significant correlation between microalbuminuria and vitamin D
deficiency. Therapy with calcitriol had a beneficial effect on the
albumin excretion rate, although this change was not significant. De
Zeeuw [35] et al, in a study on diabetic patients, showed that 2 mg/day
of paricalcitol in ad¬dition of rennin-angiotensin-aldosterone
blockers, could decrease proteinuria. Molina P [36] et al, conducted a
study on non-dialysis chronic kidney disease patients with albuminuria,
low vitamin D and high parathyroid hormone levels. They found that
cholecalciferol administration led to significant rise in mean vitamin
D levels and Urinary albumin-to-creatinine ratio significantly
decreased at 6 months in the cholecalciferol group, and there was no
change in the control group. Huang [5] et al, in a study found that
deficiency of Vitamin D was associated with microal¬buminuria ,
and administration of cholecalciferol sig¬nificantly decreased
albuminuria in the early stages of treatment. They concluded that
conventional doses of cholecalciferol may have antiproteinuric effects
on diabetic patients. Agarwal [37] et al, conducted a study in patients
with residual proteinuria and stage 2-4 chronic kidney disease (CKD).
They found a significant decrease in proteinuria in patients treated
with paricalcitol compared with the control group, after 24 weeks of
treatment. The authors concluded that the antiproteinuric effect of
paricalcitol is a potential pharmacological action that requires
further investigation. Fishbane [38] et al published a study comparing
paricalcitol with placebo in patients with stage 2-3 CKD, over a
follow-up period of six months. The decrease in the urine protein to
creatinine ratio was significant in paricalcitol group compared placebo
group. Liu [39] et al found in study of 50 patients with IgA
nephropathy and residual proteinuria >0.8g/day that patients
receiving calcitriol twice weekly had a significant decrease in
proteinuria of compared with placebo, after 48 weeks of follow-up. In
National Health and Nutrition Examination Survey (NHANES III) [40] it
was found that higher proportions of individuals with nephropathy have
vitamin D deficiency than individuals without nephropathy. This
suggests that optimum vitamin D levels should be maintained to prevent
albuminuria and diabetic nephropathy.
Our results were similar with most of the available studies in
literature. Twenty-four-hour urinary albumin excretion decreased from
200.4 ± 103.3 to198.4 ± 105.0 (p value 0.015). In
males it changed from 212.1 ± 95.4 to209.6 ±
96.9(p value 0.046) and in females it changed from 188.6 ±
111.3 to 186.8 ± 112.9 (p value 0.041). Thus we concluded
that prescription of Vit D in diabetic patients with nephropathy and
Vit D deficiency may decreased proteinuria.
Conclusion
The findings of our study have potentially important public health
implications as the vitamin D supplementation can ameliorate
albuminuria in type 2 diabetes which is the major cause of end stage
renal disease. This study encourages the design and conduct of studies
that further explore the roles of Vitamin D in nephropathy of T2DM
patients for longer durations of follow up.
Funding:
Nil, Conflict of
interest: None initiated.
Permission from IRB:
Yes
References
1. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy:
diagnosis, prevention, and treatment. Diabetes Care. 2005;
28(1):164-76. doi: 10.2337/diacare.28.1.164.
2. Rüster, C, Wolf G.
Renin–angiotensin–aldosterone system and
progression of renal disease. J Am Soc Nephrol. 2006; 17:
2985–2991.
3. Li YC, Qiao G, Uskokovic M, et al. Vitamin D: a negative
endocrine regulator of the renin-angiotensin system and blood pressure.
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):387-92. [PubMed]
4. Ramon Sonneveld, Silvia Ferrè, Joost G.J.
Hoenderop, Henry B Dijkman, Jo H.M. Berden, René J M
Bindels, et al. Vitamin D Down-Regulates TRPC6 Expression in Podocyte
Injury and Proteinuric Glomerular Disease. The American Journal of
Pathology Volume 182, Issue 4, April 2013, Pages 1196–1204.
5. Huang Y, Yu H, Lu J, Guo K, Zhang L, Bao Y, et al. Oral
supplementation with cholecalciferol 800 IU ameliorates albuminuria in
Chinese type 2 diabetic patients with nephropathy. PloS One.
2012;7(11):e50510. doi:10.1371/journal.pone.0050510.
6. Yan Zhang, Juan Kong, Dilip K Deb, et al. Vitamin D
Receptor Attenuates Renal Fibrosis by Suppressing the Renin-Angiotensin
System.J Am Soc Nephrol. 2010 Jun; 21(6): 966–973.
7. Zhang Z, Zhang Y, Ning G, et al. Combination therapy with
AT1 blocker and vitamin D analog markedly ameliorates diabetic
nephropathy: blockade of compensatory renin increase. Proc Natl Acad
Sci U S A. 2008 Oct 14;105(41):15896-90.
8. Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and
calcium in type 2 diabetes: A systematic review and meta-analysis. J
Clin Endocrinol Metab 92: 2017-2029. [PubMed]
9. G Klaus. Renoprotection with vitamin D: specific for
diabetic nephropathy. Kidney International, vol. 73, no. 2, pp.
141–143,2008.
10. V A Diaz, A G Mainous III, P J Carek, et al. The
association of vitamin D deficiency and insufficiency with diabetic
nephropathy: implications for health disparities. Journal of the
American Board of Family Medicine, vol. 22, no. 5, pp.
521–527, 2009.
11. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R,
Gilbertson D, et al. Excerpts from the United States Renal Data System
2006 Annual Data Report. Am J Kidney Dis 2007;49(1 Suppl 1): A6-7. doi:
10.1053/j. ajkd.2006.11.019. [PubMed]
12. Jacob AN, Khuder S, Malhotra N, Sodeman T, Gold JP,
Malhotra D, et al. Neural network analysis to predict mortality in
end-stage renal disease: application to United States Renal Data
System. Nephron Clin Pract. 2010;116(2):c148-58. doi: 10.1159/000315884.
13. KDIGO. Clinical Practice Guideline for the Evaluation
and Management of Chronic Kidney Disease. Kidney Int
Suppl2013;3(1):1-150.
14. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause
progressive renal damage. J Am Soc Nephrol 2006;17:2974-84. [PubMed]
15. Palmer BF. Proteinuria as a therapeutic target in
patients with chronic kidney disease. Am J Nephrol 2007;27:287-93. [PubMed]
16. Ruggenenti P, Perna A, Mosconi L, et al. Urinary protein
excretion rate is the best independent predictor of ESRF in
non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di
Studi Epidemiologici in Nefrologia» (GISEN). Kidney Int
998;53:1209-16. [PubMed]
17. Taal MW, Brenner BM. Predicting initiation and
progression of chronic kidney disease: Developing renal risk scores.
Kidney Int 2006;70:1694-705.
18. Górriz JL, Molina P, Bover J et al.
Characteristics of bone mineral metabolism in patients with stage
3–5 chronic kidney disease not on dialysis: results of the
OSERCE study. Nefrologia 2013; 33:46–60.
19. Mehrotra R, Hermah D, Budoff M et al. Hypovitaminosis D
in chronic kidney disease. Clin J Am Soc Nephrol 2008;
1144–1151. [PubMed]
20. Levin A, Bakris GL, Molitch M et al. Prevalence of
abnormal serum vitamin D, PTH, calcium, and phosphorous in patients
with chronic kidney disease. Kidney Int 2007; 71: 31–38.
21. LaClair R, Hellman RN, Karp SL et al. Prevalence of
calcidiol deficiency in CKD: a cross-sectional study across latitudes
in the United States. Am J Kidney Dis 2005; 45: 1026–1033.
22. Gonzalez ES, Sachdeva A, Oliver DA et al. Vitamin D
insufficiency and deficiency in chronic kidney disease. A single center
observational study. Am J Nephrol 2004; 24: 503–510.
23. Looker AC, Dawson-Hughes B, Calvo MS et al. Serum
25-hydroxyvitamin D status of adolescents and adults in two seasonal
subpopulations from NHANES III. Bone 2002; 30: 771–777.
24. Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc
Nephrol 2008; 3: 1555–1560. [PubMed]
25. Alvarez JA, Law J, Coakley KE et al. High-dose
cholecalciferol reduces parathyroid hormone in patients with early
chronic kidney disease: a pilot, randomized, double-blind,
placebo-controlled trial. Am J Clin Nutr 2012; 96: 672–679.
26. Marckmann P, Agerskow H, Thineshkumar S et al.
Randomized controlled trial of cholecalciferol supplementation in
chronickidney disease patients with hypovitaminosis D. Nephrol Dial
Transplant 2012; 27: 3523–3531.
27. Moe SM, Saifullah A, LaClair RE et al. A randomized
trial of cholecalciferol versus doxercalciferol for lowering
parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol
2010; 5: 299–306.
28. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al.
Renoprotective role of the vitamin D receptor in diabetic nephropathy.
Kidney Int. 2008;73(2):163-71. doi: 10.1038/sj.ki.5002572.
29. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S,
Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in
subtotally nephrectomized rats. Kidney Int. 1998;53(6):1696-705. doi:
10.1046/j.1523- 1755.1998.00951. [PubMed]
30. Lips P. Vitamin D deficiency and secondary
hyperparathyroidism in the elderly: Endocr Rev. 2001. [PubMed]
31. Ahmadi N, Mortazavi M, Iraj B, et al. Whether vitamin D3
is effective in reducing proteinuria in type 2 diabetic patients. J Res
Med Sci. 2013;18(5):374-7. [PubMed]
32. Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD,
Hill PD, et al. Oral cholecalciferol decreases albuminuria and urinary
TGF-beta1 in patients with type 2 diabetic nephropathy on established
renin-angiotensin-aldosterone system inhibition. Kidney Int.
2011;80(8):851-60. [PubMed]
33. Ali Momeni, Mahmood Mirhosseini, Mohsen Kabiri, et al.
Effect of vitamin D on proteinuria in type 2 diabetic patients. J
Nephropathol. 2017 Jan; 6(1): 10–14. [PubMed]
34. Bonakdaran S, Hami M, Hatefi A. The effects of
calcitriol on albuminuria in patients with type-2 diabetes mellitus.
Saudi J Kidney Dis Transpl. 2012;23(6):1215- 20. doi:
10.4103/1319-2442.103562.
35. De Zeeuw D, Agarwal R, Amdahl M, Audhya P et al:
Selective vitamin D receptor activation with paricalcitol for reduction
of albuminuria in patients with type 2 diabetes (VITAL study): a
randomised controlled trial. Lancet. 2010 Nov6 6; 376(9752):1543-51.
36. Molina P, Górriz JL, Molina MD, et al. The
effect of cholecalciferol for lowering albuminuria in chronic kidney
disease: a prospective controlled study. Nephrol Dial Transplant (2014)
29 (1): 97-109. [PubMed]
37. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et
al. Antiproteinuric effect of oral paricalcitol in chronic kidney
disease. Kidney Int 2005;68:2823-8. [PubMed]
38. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N,
Durie N. Oral paricalcitol in the treatment of patients with CKD and
proteinuria: a randomized trial. Am J Kidney Dis 2009;54:647- 52. [PubMed]
39. Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY. Oral calcitriol
for reduction of proteinuria in patients with IgA nephropathy: a
randomized controlled trial. Am J Kidney Dis 2012;59:67-74. [PubMed]
40. R Scragg, M Sowers, C Bell. Serum 25-hydroxyvitamin D, diabetes,
and ethnicity in the Third National Health and Nutrition Examination
Survey. Diabetes Care, vol. 27, no. 12,pp. 2813–2818, 2004. [PubMed]
How to cite this article?
Wani Z, Telwani A, Wani S, Shah A., Ummer J. Effect of parenteral
vitamin D (D3) on albuminuria in T2DM patients. Int J Med Res Rev
2017;5(06):604-609. doi:10.17511/ijmrr. 2017.i06.09.